🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

IRD IRD

Company Profile ↓
$3.78
+250.00% 1Y
P/E-4.72
52W High$5.75
52W Low$1.06
EPS (TTM)$-0.80

Company Overview

IRD (IRD) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Recent Developments

  • Dec 2025 Revenue of $14.20M (+29.1% YoY); net profit $-49.59M.
  • Trailing 12 Months Year-on-year growth — revenue +29.1%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:29.15%

Stock Price Performance

1 Year:+250.00%
6 Months:+57.50%
3 Months:-27.31%
1 Month:-6.67%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 58% of range
$1.06 $5.75
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)54.56 · Neutral
Price Performance
1M-6.67%
3M-27.31%
6M+57.50%
1Y+250.00%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 34.3% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-4.72
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
29.15%
Earnings (YoY)
-

Profitability & Returns

ROCE
-90.90%
ROE
-
ROA
-98.70%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.75
EPS (TTM)
$-0.80

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$66.79M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
11.02%
Chg in Prom Hold
-
FII / Inst Holding
55.71%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$14.20M
EBITDA
-
Free Cash Flow
$-6.80M
Operating Cash Flow
$-35.25M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue ----------------------00-100.00K489.00K0001.75M3.67M11.94M1.71M1.11M3.87M4.37M2.88M3.08M2.16M
Operating Income -3.14M-3.85M-4.42M-4.82M-4.66M-4.37M-4.86M-3.91M-3.72M-3.92M-3.95M-4.28M-4.22M-4.90M-5.89M-5.00M-4.68M-4.97M-3.94M-2.99M-2.28M-2.73M-1.26M-1.95M-5.19M-7.14M-4.23M-6.51M-4.94M-4.54M-6.13M-5.39M6.39M-7.71M-8.33M-8.01M-9.93M-8.91M-8.31M-14.36M
Net Income -1.91M-2.21M-4.27M-3.23M-4.03M-2.85M-4.15M-1.77M-2.87M-525.48K-21.61M947.06K-1.04M-3.59M-2.07M-3.84M-5.34M-3.12M-2.34M-2.46M-1.96M-3.09M-1.60M-1.25M-39.01M-7.14M-4.23M-6.59M-4.93M-4.53M-5.79M-4.96M5.56M-7.11M-7.76M-7.53M-8.19M-7.42M-17.45M-65.53M
Diluted EPS --------0.08---0.910.03-0.04-0.12--0.12------0.87-0.43-0.33-3.57-0.52-0.25-0.35-0.25-0.22-0.28-0.240.25-0.29-0.30-0.29-0.24-0.12-0.25-0.75
R&D Expense 1.82M-2.89M3.24M3.10M-3.47M2.24M2.30M-2.26M2.54M2.64M-4.06M3.43M2.89M-2.24M1.65M1.13M456.79K231.61K149.59K----------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2002Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------00000-----3.00M0589.00K39.85M19.05M10.99M14.20M
Operating Income --------6.47M-10.31M-16.13M-6.58M-7.98M-13.27M-18.26M-16.41M-17.35M-20.54M-4.19M-19.97M-22.70M18.23M-10.56M-62.07M-38.60M
Net Income -1.18M-2.78M-3.27M-6.35M-6.49M-4.44M-3.68M-2.90M-14.02M-11.34M-6.23M-9.50M-18.52M-14.38M-9.31M-25.29M-14.37M-6.17M-24.62M-56.69M17.89M-9.99M-57.53M-49.59M
Diluted EPS -------------------5.28-3.820.87-0.46-2.15-0.80
R&D Expense -------3.18M3.93M11.99M3.39M3.25M7.02M12.15M10.09M10.72M13.11M5.48M------

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2001Dec 2002Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets ---------16.22M13.69M14.92M19.56M33.53M24.81M21.04M28.29M16.04M1.78M17.68M26.08M48.99M53.95M36.86M50.24M
Total Equity 3.89M2.71M2.48M-564.17K4.83M3.21M958.19K-2.60M4.90M10.40M10.71M9.53M12.63M26.58M18.78M17.06M16.77M-1.70M-7.56M-13.47M22.22M46.24M49.91M6.72M15.35M
Cash & Equivalents -------369.13K7.30M12.34M9.86M13.49M18.69M9.83M10.20M11.58M8.90M8.74M12.20M-24.53M42.63M50.50M30.32M45.09M
Long Term Debt -----------------------01.13M
Total Liabilities ---------5.82M2.98M5.39M6.93M6.95M6.03M3.99M11.52M5.48M9.34M31.15M3.85M2.75M4.04M11.29M34.90M
Current Liabilities -----------------3.15M9.34M3.19M3.85M2.75M4.04M11.29M7.78M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ------15.42M-18.84M-3.59M-6.80M-19.37M14.31M-1.11M-25.58M-35.25M
Investing Cash Flow 1.34M-660.04K-545.92K2.19M845.52K-9.37M11.91M-25.00K539.00K-100.00K001.21M0
Financing Cash Flow 10.73M12.69M13.60M8.05M12.34M22.11M6.77M4.70M21.12M27.61M3.79M8.98M4.19M50.02M
Capital Expenditure --------25.00K-0-----
Free Cash Flow --------3.62M-6.80M-----
Share Buybacks 000-----------

Ratios (Annual)

Figures in %.

Metric Dec 2002Dec 2003Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------------------------
Operating Margin % ------------------139.8%--3,854.8%45.7%-55.5%-564.7%-271.9%
Net Margin % ------------------205.6%--9,625.3%44.9%-52.4%-523.4%-349.3%
ROE % -43.5%-112.0%580.2%-131.5%-201.8%-463.6%141.5%-59.2%-134.9%-106.0%-65.3%-75.2%-69.7%-76.6%-54.6%-150.8%845.7%81.6%182.8%-255.1%38.7%-20.0%-855.6%-323.1%
ROCE % -----------------159.3%55.5%-137.7%-102.2%39.4%-21.2%-242.8%-90.9%

Shareholding Pattern

Insiders
11.02%
Institutions
55.71%
Public Float
62.61%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IRD

Google News Mon, 03 Aug 2026

Opus Genetics expects data in 2027 from one-time gene therapy trial - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOQVRfd3FxRXVQcEVCa0FwZ3lyNDFKejFGREZNQVhDVmlVLTRMY2o3NnBtdE13ZXBLUHkzYldOb3JkamV4OFZrQ3NxNnRqdFM1Wi1aZ0ZfT3JBX0ozeERhOHdCMkdqczlPemxRUmxQdE1VTmV2NGZsTW9DMXNqckF2SkdKVWpNMW50OVhpLT…

Google News Sat, 01 Aug 2026

Opus Genetics, Inc. Revenue Breakdown – NASDAQ:IRD - TradingView

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE9uWjg3RnE1M0dTWXhkUzhIYW1iT2pUT2NYY1JEMnBPZFJlNnRmN2NOR1JkcmNVeWZQejdVQXgyS0g3cnRKd2wtRnpYeWlqVnBYQW9JME55SmVTR3hqMndYVWhvaE55ZmpKWGdBMmt4alF3bi1BNHc?oc=5" target="_blank">Opus Gen…

Google News ue, 04 Aug 2026

IRD Looks 933.3% Overvalued on GF Value™ - GuruFocus

<a href="https://news.google.com/rss/articles/CBMikgFBVV95cUxPQ3p3dGlVcG93Uk5hWHBOcnNmN1ZSN2k1OW8xQlhHQXR6YU96Z2NsSk93VDZzckhQS1NhNGM5M0E1UVpPYTV0Y2JoWGpqbTMxbmlTVWtKQ1doc2ZYUVgtRDVCQjBaQk0yR0dGMDZRemlDTmhmVW5oZVYzZXRsdXA0MEYySlhlaXkxZDdFZE…

Google News ue, 05 May 2026

Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ Stocks - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxNVXhhaF91THc1M0VGS3d0bFc1RkpsbUMtbkZnZzNNVGhheUNXLXVJTnRTQ2ZCbG1YZnJaTDlXWFBSU0pLbkRSS2hfc3RyRFpKY3RjS3RBeHU4SzhXNUhudF9oSFRvbWNlSkdtSnFoMFpxYjY2bElFLVh1VlVtSFgydlFHVk1ESU9aajk2TS…

Google News Mon, 03 Aug 2026

IRD|Opus Genetics Inc|Price:3.645|Chg%:-0.065 - TradingKey

<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTFB3T0RsRzM4elRxMTdvTzZqOS1FWDhNTkUwYzBZS3JocXc2Z2c4SnlYSWI5TVdyX1BDR3luMWtvVnhaTm1SZ1h4eENxQkJHNDhpd0p6akdVbHRiUnJHdHhhQmxBWWZQMFhYUElCcw?oc=5" target="_blank">IRD|Opus Genetics Inc…

Google News Mon, 27 Jul 2026

Insider Sale: President of $IRD Sells 7,429 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOSkctUjJLY1VsczdXUE5wU01yNFNTblQwUF9hRmpIc29GeHVNbnZZTFRld2VsTG5UclZUYkZFYjQxcHVNNlVFd3p4elRpcFROMGFkMnM2UVhteEl4ZWZhR1Y2RWdUNjVRM0Rqemt1MExNdzBfNE9PRGpCN0NZeUhyckk2R2sxaUtub3d1ND…

IRD — Frequently Asked Questions

What is the current share price of IRD?

As of 2026-08-05 17:25 PDT, IRD trades at $3.78 on NASDAQ/NYSE. Its 52-week range is $1.06 to $5.75.

What is the P/E ratio of IRD?

IRD trades at a trailing price-to-earnings (P/E) ratio of -4.72.

Is IRD a good stock to buy?

This page provides a data-driven analysis of IRD, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space